Cargando…
Expanding the search for germline pathogenic variants for breast cancer. How far should we go and how high should we jump? The missed opportunity!
Since the identification of BRCA1 and BRCA2 genes 3 decades ago, genetic testing and genetic counseling have become an integral part of routine clinical practice. The risk of breast cancer among carriers of germline pathogenic variants, like BRCA1 and BRCA2, is well established. Risk-reducing interv...
Autor principal: | Abdel-Razeq, Hikmat |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
PAGEPress Publications, Pavia, Italy
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8256373/ https://www.ncbi.nlm.nih.gov/pubmed/34267891 http://dx.doi.org/10.4081/oncol.2021.544 |
Ejemplares similares
-
Undergraduate medical education; how far should we go?
por: Benamer, Hani TS
Publicado: (2007) -
Extending Treatment Networks in Health Technology Assessment: How Far Should We Go?
por: Caldwell, Deborah M., et al.
Publicado: (2015) -
Staged surgical approach for metastatic GIST, how far should we go? Case report
por: Alqattan, Abdullah Saleh, et al.
Publicado: (2021) -
Ultra-protective tidal volume: how low should we go?
por: Costa, Eduardo LV, et al.
Publicado: (2013) -
Delays in Initiating Anti-Cancer Therapy for Early-Stage Breast Cancer—How Slow Can We Go?
por: Abdel-Razeq, Hikmat, et al.
Publicado: (2023)